Table 2.
Histopathological tumor characteristics stratified by review classification categories
| Total | True | Missed | Minimal signs | |||||
|---|---|---|---|---|---|---|---|---|
| n = 1225 | 100% | n = 567 | n = 266 | n = 392 | ||||
| Histopathological type | ||||||||
| DCIS | 180 | 15% (13, 17) | 98 | 17% (14, 21) | 32 | 12% (8, 17) | 50 | 13% (10, 17) |
| Invasive carcinoma of NST | 880 | 72% (69, 74) | 407 | 72% (68, 76) | 194 | 73% (67, 78) | 279 | 71% (66, 76) |
| ILC | 94 | 8% (6, 9) | 35 | 6% (4, 9) | 21 | 8% (5, 12) | 38 | 10% (7, 13) |
| Other invasive carcinomas | 71 | 6% (5, 7) | 27 | 5% (3, 7) | 19 | 7% (4, 11) | 25 | 6% (4, 9) |
| DCIS | 180 | 98 | 32 | 50 | ||||
| Tumor diameter | ||||||||
| Mean ± SD | 20 mm ± 16 | 20 mm ± 14 | 18 mm ± 14 | 23 mm ± 21 | ||||
| Median (IQR) | 15 mm (10, 27) | 15 mm (10, 26) | 15 mm (8, 25) | 17 mm (10, 33) | ||||
| Data not available | 23 | 15 | 2 | 6 | ||||
| Histological grade | ||||||||
| Grade 1 | 23 | 14% (9, 21) | 9 | 10% (5, 19) | 3 | 10% (2, 27) | 11 | 24% (13, 39) |
| Grade 2 | 18 | 11% (7, 17) | 10 | 12% (6, 20) | 3 | 10% (2, 27) | 5 | 11% (4, 24) |
| Grade 3 | 121 | 75% (67, 81) | 68 | 78% (68, 86) | 23 | 79% (60, 92) | 30 | 65% (50, 79) |
| Data not available | 18 | 11 | 3 | 4 | ||||
| Invasive cancer | 1045 | 469 | 234 | 342 | ||||
| Tumor diameter (mm) | ||||||||
| Mean ± SD | 15 mm ± 10 | 15 mm ± 9 | 16 mm ± 10 | 15 mm ± 10 | ||||
| Median (IQR) | 13 mm (9, 19) | 12 mm (9, 18) | 13 mm (10, 20) | 13 mm (9, 19) | ||||
| Data not available | 23 | 12 | 5 | 6 | ||||
| Histological grade | ||||||||
| Grade 1 | 288 | 28% (25, 30) | 103 | 23% (19, 27) | 73 | 32% (26, 38) | 112 | 33% (28, 38) |
| Grade 2 | 519 | 50% (47, 54) | 216 | 47% (43, 52) | 124 | 54% (47, 61) | 179 | 52% (47, 58) |
| Grade 3 | 222 | 22% (19, 24) | 138 | 30% (26, 35) | 33 | 14% (10, 20)* | 51 | 15% (11, 19)* |
| Data not available | 16 | 12 | 4 | |||||
| Lymph node status | ||||||||
| Negative | 797 | 80% (77, 82) | 353 | 78% (74, 82) | 182 | 81% (76, 86) | 262 | 81% (76, 85) |
| Data not available | 47 | 19 | 10 | 18 | ||||
| Hormonal status | ||||||||
| ER positive | 919 | 91% (89, 93) | 387 | 86% (82, 89) | 215 | 95% (92, 98)* | 317 | 95% (92, 97)* |
| Data not available | 35 | 18 | 8 | 9 | ||||
| PR positive | 730 | 73% (70, 75) | 303 | 67% (62, 71) | 173 | 78% (72, 83) | 254 | 77% (72, 81) |
| Data not available | 39 | 16 | 11 | 12 | ||||
Unless otherwise specified, data are the number of patients and 95% confidence intervals in parentheses
DCIS ductal carcinoma in situ, NST no special type, ILC invasive lobular carcinoma, ER estrogen receptor, PR progesterone receptor, SD standard deviation, IQR interquartile range
*p < 0.001, compared with true